设计的抑制剂,以向男性-混合血统白血病相互作用的抑制剂
Moses N Arthur1,2, Kristeen Bebla3,4, Emmanuel Broni3
1Department of Parasitology, Noguchi Memorial Institute for Medical Research (NMIMR), College of Health Sciences (CHS), University of Ghana, Legon, Accra LG 581, Ghana.
概括
研究人员发现了新型天然化合物,可以抑制menin,这是混合血统白血病 (MLL) 中的关键蛋白质. 这些化合物显示出作为MLL潜在的新治疗方法的希望,这是一种具有挑战性的婴儿白血病.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 计算化学的计算化学
背景情况:
- 混合血统白血病 (MLL) 构成了重大的治疗挑战,特别是在婴儿中,因为治疗选择有限.
- MLL的特征是染色体转位涉及KMT2A基因,导致瘤性MLL融合蛋白.
- 脑膜蛋白作为MLL融合蛋白的关键瘤性辅因子,为新型抗白血病疗法提供了可行的标.
研究的目的:
- 通过基于结构的药物设计 (SBDD) 方法识别meni蛋白的新兴抑制剂.
- 从天然产品库中发现MLL介导白血病的潜在治疗剂.
主要方法:
- 使用EasyModeller 4.0和I-TASSER.生成了menin的3D蛋白质模型 (蛋白质ID:4GQ4).
- 通过使用AutoDock Vina.虚拟选了25131个自然连接体的库,以对抗menin蛋白.
- 进行了分子动力学模拟和MM/PBSA计算,以评估敏结合体复合体的稳定性和结合机制.
主要成果:
- 确定了10种具有显著结合能量的自然化合物,包括ZINC000103526876 (-11.0 kcal/mol).
- 确定了关键的氨基酸残留物参与联结,如Phe243,Met283和Cys246.
- 对于特定化合物 (MI-2-2,PubChem CIDs 71777742,36294) 已证实具有抗阴膜性质,并预测了具有微不足道毒性的有利的药理学特征.
结论:
- 已识别的天然化合物显示出对MLL介导白血病的新型治疗剂的潜力.
- 需要进一步的实验验证,以确认这些有前途的化合物的抗白血病活性.
- 这些发现支持探索天然产品作为开发有效治疗MLL的来源.
相关概念视频
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K


